News Room
News Releases
Oct. 18, 2021 (PDF/247KB) Licensing
Sumitomo Dainippon Pharma and BehaVR announce landmark deal for multiple virtual reality digital therapeutics
Oct. 11, 2021 (PDF/344KB) Products
Enzyvant Receives FDA Approval for RETHYMIC (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Sep. 30, 2021 (PDF/218KB) Licensing
Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds
Sep. 14, 2021 R&D
Posted Video of Frontier Business Meeting - FBO Showcase - [Webcast]
Sep. 10, 2021 (PDF/120KB) Products
Sumitomo Dainippon Pharma Announces Launch of TWYMEEG for the Treatment of Type 2 Diabetes in Japan
Sep. 10, 2021 (PDF/109KB) R&D
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis
Sep. 08, 2021 (PDF/18,450KB) R&D
Posted Presentation Material (Frontier Business Meeting - FBO Showcase -)
Sep. 03, 2021 (PDF/152KB) R&D
Sumitomo Dainippon Pharma and Pixie Dust Technologies Sign Joint R&D Agreement on Communication Support Smart Glasses for Hard of Hearing People
Sep. 03, 2021 (PDF/215KB) Licensing
Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
Sep. 02, 2021 (PDF/99KB) Corporate
Sumitomo Dainippon Pharma Opens a Representative Office in Vietnam
Documents for Press
Nov. 01, 2019 (PDF/1,557KB) Corporate
Press Conference Presentation for Definitive Agreement for Strategic Alliance with Roivant Sciences
Oct. 28, 2019 (PDF/926KB) Finances
Press Conference Presentation for Q2 FY2019 (April 1 to September 30, 2019)
Dec. 02, 2013 (PDF/414KB) R&D
Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)